Skip to main content

TERIFLUNOMIDE INTAS, TERIFLAGIO, TERINTAS (Accord Healthcare Pty Ltd)

Product name
TERIFLUNOMIDE INTAS, TERIFLAGIO, TERINTAS
Date registered
Evaluation commenced
Decision date
Approval time
141 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication

TERIFLUNOMIDE INTAS, TERIFLAGIO, TERINTAS (film-coated tablets) are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Help us improve the Therapeutic Goods Administration site